Trade Aridis Pharmaceuticals, Inc. - ARDSus CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.0059 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.023457% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.001235% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 0.2533 |
| Open | 0.294 |
| 1-Year Change | -72.26% |
| Day's Range | 0.2635 - 0.312 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Jul 18, 2023 | 0.3090 | 0.0041 | 1.34% | 0.3049 | 0.3209 | 0.2601 |
| Jul 17, 2023 | 0.2533 | -0.0607 | -19.33% | 0.3140 | 0.3166 | 0.2491 |
| Jul 14, 2023 | 0.3153 | -0.0302 | -8.74% | 0.3455 | 0.3455 | 0.3090 |
| Jul 13, 2023 | 0.3490 | 0.0454 | 14.95% | 0.3036 | 0.3588 | 0.2790 |
| Jul 12, 2023 | 0.3289 | -0.0499 | -13.17% | 0.3788 | 0.3987 | 0.3153 |
| Jul 11, 2023 | 0.2606 | 0.0114 | 4.57% | 0.2492 | 0.2669 | 0.2490 |
| Jul 10, 2023 | 0.2617 | 0.0227 | 9.50% | 0.2390 | 0.2638 | 0.2390 |
| Jul 7, 2023 | 0.2491 | 0.0257 | 11.50% | 0.2234 | 0.2502 | 0.2234 |
| Jul 6, 2023 | 0.2263 | 0.0046 | 2.07% | 0.2217 | 0.2321 | 0.2213 |
| Jul 5, 2023 | 0.2272 | 0.0080 | 3.65% | 0.2192 | 0.2332 | 0.2192 |
| Jul 3, 2023 | 0.2148 | 0.0006 | 0.28% | 0.2142 | 0.2259 | 0.2142 |
| Jun 30, 2023 | 0.2144 | -0.0025 | -1.15% | 0.2169 | 0.2169 | 0.1993 |
| Jun 29, 2023 | 0.2129 | 0.0037 | 1.77% | 0.2092 | 0.2167 | 0.2092 |
| Jun 28, 2023 | 0.2116 | -0.0276 | -11.54% | 0.2392 | 0.2392 | 0.2092 |
| Jun 27, 2023 | 0.2413 | -0.0088 | -3.52% | 0.2501 | 0.2531 | 0.2345 |
| Jun 26, 2023 | 0.2492 | -0.0099 | -3.82% | 0.2591 | 0.2591 | 0.2491 |
| Jun 23, 2023 | 0.2597 | 0.0051 | 2.00% | 0.2546 | 0.2603 | 0.2492 |
| Jun 22, 2023 | 0.2566 | -0.0025 | -0.96% | 0.2591 | 0.2591 | 0.2541 |
| Jun 21, 2023 | 0.2565 | 0.0043 | 1.70% | 0.2522 | 0.2601 | 0.2501 |
| Jun 20, 2023 | 0.2552 | -0.0014 | -0.55% | 0.2566 | 0.2671 | 0.2516 |
Why choose Capital.com? Our numbers speak for themselves.
Capital.com Group720K+
Traders
100K+
Active clients monthly
$240B+
Monthly trading volume
$60M+
Withdrawn each month
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 3:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
Aridis Pharmaceuticals, Inc. Company profile
About Aridis Pharmaceuticals Inc
Aridis Pharmaceuticals, Inc. is a late-stage biopharmaceutical company. The Company is focused on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies (mAbs) to treat life-threatening infections. The Company's proprietary product pipeline is comprised of fully human mAbs targeting specific pathogens associated with life-threatening bacterial and viral infections, primarily hospital-acquired pneumonia (HAP), ventilator-associated pneumonia (VAP), cystic fibrosis and COVID-19. The Company's lead product candidate, AR-301, targets the alpha toxin produced by gram-positive bacteria Staphylococcus aureus (S. aureus), a common pathogen associated with HAP and VAP. Its clinical development activities are focused on AR-301, AR-712, and AR-501. Its development of antibody discovery and production platform technology called aPEXTM extends the capabilities of MabIgX, its differentiated antibody discovery platform.
Financial summary
BRIEF: For the nine months ended 30 September 2021, Aridis Pharmaceuticals Inc revenues decreased 45% to $548K. Net loss applicable to common stockholders increased from $16.5M to $37.5M. Revenues reflect License revenue decrease of 87% to $131K. Higher net loss reflects Research and development - Balancing val increase from $12.3M to $28.9M (expense), General and administrative - Balancing increase of 11% to $4.1M (expense).
| Industry: | Bio Therapeutic Drugs |
983 University Avenue, Bldg. B
LOS GATOS
CALIFORNIA 95032
US
News
GME shares price forecast: Third-party price target
Read our GameStop (GME) share price forecast for 2025 and beyond, with insights from third-party analysts and market experts
11:40, 28 April 2025
ECB interest-rate forecasts – Projections for the next five years
The European Central Bank (ECB) plays a pivotal role in the economic stability of the eurozone, meaning ECB interest-rate forecasts are key to understanding how financial and economic scenarios might evolve.
14:37, 10 April 2025
BlackRock shareholders: Who owns the most BLK stock?
BlackRock is the leading asset manager in the world – but who are its biggest shareholders? Read on to find out.
13:46, 9 April 2025
Bitcoin price predictions 2025–2050: third-party price target
We examine bitcoin price predictions for 2025 and beyond, with insights from third-party analysts and market experts.
10:28, 9 April 2025
Tesla (TSLA) stock forecast 2025 and beyond: third-party Tesla price target
Where will Tesla’s stock be in five years? Can the EV company keep its crown?
08:19, 9 April 2025
JasmyCoin price predictions 2025-2030: Third-party price target
How might JASMY behave in the future?
16:13, 8 April 2025
Australian interest-rate projections: where will rates be in 5 years?
As one of the most closely watched economic indicators, Australian interest-rate projections offer valuable insight into the future of the country’s economy.
21:37, 7 April 2025People also watch
Still looking for a broker you can trust?
Join the 720,000+ traders worldwide that chose to trade with Capital.com